PL2459167T3 - Preparat podskórny przeciwciała anty-her2 - Google Patents
Preparat podskórny przeciwciała anty-her2Info
- Publication number
- PL2459167T3 PL2459167T3 PL10737891T PL10737891T PL2459167T3 PL 2459167 T3 PL2459167 T3 PL 2459167T3 PL 10737891 T PL10737891 T PL 10737891T PL 10737891 T PL10737891 T PL 10737891T PL 2459167 T3 PL2459167 T3 PL 2459167T3
- Authority
- PL
- Poland
- Prior art keywords
- her2 antibody
- antibody formulation
- subcutaneous anti
- subcutaneous
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09167025 | 2009-07-31 | ||
EP10737891.1A EP2459167B2 (en) | 2009-07-31 | 2010-07-28 | Subcutaneous anti-her2 antibody formulation |
PCT/EP2010/060930 WO2011012637A2 (en) | 2009-07-31 | 2010-07-28 | Subcutaneous anti-her2 antibody formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2459167T3 true PL2459167T3 (pl) | 2013-10-31 |
PL2459167T5 PL2459167T5 (pl) | 2023-12-11 |
Family
ID=43500473
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10737891.1T PL2459167T5 (pl) | 2009-07-31 | 2010-07-28 | Preparat podskórny przeciwciała anty-her2 |
PL13166031.8T PL2687202T3 (pl) | 2009-07-31 | 2010-07-28 | Podskórny preparat przeciwciała anty-HER2 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13166031.8T PL2687202T3 (pl) | 2009-07-31 | 2010-07-28 | Podskórny preparat przeciwciała anty-HER2 |
Country Status (41)
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2399605A1 (en) | 2005-02-23 | 2011-12-28 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
JP2010520225A (ja) | 2007-03-02 | 2010-06-10 | ジェネンテック, インコーポレイテッド | 低her3発現に基づくher二量化インヒビターに対する応答を予測する方法 |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
CN102471377B (zh) * | 2009-07-24 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 优化抗体的生产 |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
CN102686241A (zh) * | 2009-12-29 | 2012-09-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
PL2766040T3 (pl) | 2011-10-14 | 2019-11-29 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi |
WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
AR090244A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Formulacion de anticuerpo anti-selectina p |
US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
US20160002624A1 (en) | 2012-05-17 | 2016-01-07 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
EP3427721A1 (en) | 2012-05-18 | 2019-01-16 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
HUE043121T2 (hu) | 2012-06-21 | 2019-08-28 | Synthon Biopharmaceuticals Bv | Eljárás antitest tisztítására |
WO2014052713A2 (en) | 2012-09-27 | 2014-04-03 | Massachusetts Institute Of Technology | Her2-and vegf-a-binding proteins with enhanced stability |
KR101454646B1 (ko) * | 2012-11-05 | 2014-10-27 | (주)한국비엠아이 | 히알루로니다아제의 안정화 제제 및 이를 포함하는 액상제제 |
DK2934582T3 (da) * | 2012-12-21 | 2020-02-24 | Ichnos Sciences SA | Anti-her2-antistofformulering |
MY185551A (en) * | 2013-03-13 | 2021-05-19 | Genentech Inc | Antibody formulations |
KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
MY173295A (en) | 2013-04-16 | 2020-01-14 | Genentech Inc | Pertuzumab variants and evaluation thereof |
CN105722500B (zh) * | 2013-09-11 | 2019-08-30 | 伊戈尔生物药品股份有限公司 | 包含离子性液体的液体蛋白质制剂 |
SG11201607104RA (en) * | 2014-02-28 | 2016-09-29 | Merus Nv | Antibody that binds erbb-2 and erbb-3 |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
CN104906576B (zh) * | 2014-03-13 | 2018-06-19 | 四川科伦博泰生物医药股份有限公司 | 可供皮下注射的高浓度抗vegf抗体配制剂 |
KR20160141857A (ko) | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
US20170204149A1 (en) | 2014-06-23 | 2017-07-20 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof |
CN112851790A (zh) | 2014-06-23 | 2021-05-28 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
AU2015318001B2 (en) | 2014-09-15 | 2021-03-25 | Genentech, Inc. | Antibody formulations |
CN107406490A (zh) | 2015-01-23 | 2017-11-28 | 诺华股份有限公司 | 具有改善的半衰期的合成apelin脂肪酸缀合物 |
US9824394B1 (en) | 2015-02-06 | 2017-11-21 | Square, Inc. | Payment processor financing of customer purchases |
US9779432B1 (en) | 2015-03-31 | 2017-10-03 | Square, Inc. | Invoice financing and repayment |
EP3302551A2 (en) | 2015-05-30 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer |
PE20181323A1 (es) * | 2015-06-22 | 2018-08-14 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina |
KR20170004814A (ko) * | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
WO2017003270A1 (ko) * | 2015-07-02 | 2017-01-05 | 주식회사 녹십자 | 헌터증후군 치료제 및 치료방법 |
UA124259C2 (uk) * | 2015-09-28 | 2021-08-18 | Сужоу Санкадіа Байофармасьютікалз Ко., Лтд. | Фармацевтичне одержання стабільного анти-pd-1 антитіла та його застосування в медицині |
DK3365373T3 (da) | 2015-10-23 | 2021-04-06 | Merus Nv | Bindingsmolekyler, der hæmmer cancervækst |
MA53356B1 (fr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
CN108367053A (zh) | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
PT3479819T (pt) | 2016-06-30 | 2024-04-15 | Celltrion Inc | Preparação farmacêutica líquida estável |
KR20230035706A (ko) | 2016-09-14 | 2023-03-14 | 테네오원, 인코포레이티드 | Cd3 결합 항체 |
KR20230052309A (ko) | 2016-12-21 | 2023-04-19 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
MX2019007801A (es) | 2016-12-28 | 2019-10-30 | Genentech Inc | Tratamiento de cáncer avanzado con expresión de her2. |
EP3570884B1 (en) | 2017-01-17 | 2020-09-30 | Genentech, Inc. | Subcutaneous her2 antibody formulations |
CN117180422A (zh) | 2017-03-02 | 2023-12-08 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
IL269656B1 (en) | 2017-03-31 | 2024-02-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3624846A1 (en) | 2017-05-16 | 2020-03-25 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
JP2020521788A (ja) * | 2017-06-02 | 2020-07-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 免疫アゴニストの投与経路 |
CN117567624A (zh) | 2017-06-20 | 2024-02-20 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
SG11201912774RA (en) | 2017-06-20 | 2020-01-30 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
US11506668B2 (en) | 2017-06-23 | 2022-11-22 | Engebraaten Olav | Diagnosis and treatment of cancer |
AU2018308930A1 (en) * | 2017-07-28 | 2020-02-06 | F. Hoffmann-La Roche Ag | Bispecific antibody formulation |
MA49846A (fr) | 2017-08-09 | 2020-06-17 | Merus Nv | Anticorps qui se lient à l'egfr et à cmet |
US20200207867A1 (en) | 2017-09-13 | 2020-07-02 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
MA50239A (fr) * | 2017-09-15 | 2020-07-22 | Amgen Inc | Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique |
MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
CN107898756B (zh) * | 2017-12-22 | 2020-11-20 | 东曜药业有限公司 | 一种用于皮下或肌肉注射的高浓度尼妥珠单抗制剂及其制备方法和应用 |
WO2019123427A1 (en) | 2017-12-22 | 2019-06-27 | Novartis Ag | Methods of treating metabolic disorders with fgf21 variants |
JOP20200157A1 (ar) | 2017-12-22 | 2022-10-30 | Teneobio Inc | أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22 |
EP3560945A1 (en) | 2018-04-27 | 2019-10-30 | F. Hoffmann-La Roche AG | Methods for purification of polypeptides using polysorbates |
JOP20200292A1 (ar) * | 2018-05-16 | 2020-11-15 | Stichting Vumc | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان |
CN110732023B (zh) * | 2018-07-18 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种her2抗体药物组合物及其用途 |
WO2020017901A1 (ko) * | 2018-07-19 | 2020-01-23 | (주)셀트리온 | 안정한 액체 약제학적 제제 |
MX2021000708A (es) | 2018-07-20 | 2021-03-25 | Teneobio Inc | Anticuerpos de cadena pesada que se unen al cd19. |
AU2019339344A1 (en) | 2018-09-12 | 2021-03-18 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
WO2020060192A1 (ko) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제 |
AU2019367218A1 (en) | 2018-10-26 | 2021-06-03 | TeneoFour, Inc. | Heavy chain antibodies binding to CD38 |
EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
CN111202845A (zh) * | 2018-11-22 | 2020-05-29 | 上海医药集团股份有限公司 | 包含抗cd20抗体的药物配制剂及其制备方法和应用 |
WO2020109978A1 (en) | 2018-11-26 | 2020-06-04 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
US20220072167A1 (en) * | 2019-01-04 | 2022-03-10 | Actinium Pharmaceuticals, Inc. | Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates |
EP3914282A1 (en) | 2019-01-25 | 2021-12-01 | Ospedale San Raffaele S.r.l. | Inhibitor of dux4 and uses thereof |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
KR102507853B1 (ko) * | 2019-03-25 | 2023-03-10 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
EP3947470A1 (en) | 2019-04-05 | 2022-02-09 | TeneoBio, Inc. | Heavy chain antibodies binding to psma |
CN110179746A (zh) * | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
UY38748A (es) | 2019-06-14 | 2021-01-29 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
CN114341185A (zh) | 2019-06-19 | 2022-04-12 | 希沃尔拜克治疗公司 | 抗间皮素抗体及其免疫缀合物 |
EP4004050A2 (en) | 2019-07-30 | 2022-06-01 | QLSF Biotherapeutics Inc. | Multispecific binding compound that bind to lfrrc15 and cd3 |
US20220281972A1 (en) * | 2019-08-07 | 2022-09-08 | Innovent Biologics (Suzhou) Co., Ltd. | Formulation comprising anti-pd-1/her2 bispecific antibody, method for preparing same and use thereof |
GB201913697D0 (en) | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
WO2021079337A1 (en) * | 2019-10-23 | 2021-04-29 | Cadila Healthcare Limited | Pharmaceutical formulation of anti-her2 antibody and preparation thereof |
KR20210059646A (ko) * | 2019-11-15 | 2021-05-25 | 삼성바이오에피스 주식회사 | 항체 의약품용 액상 조성물 |
WO2021097220A1 (en) | 2019-11-15 | 2021-05-20 | Seagen Inc. | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate |
PE20221281A1 (es) * | 2019-12-09 | 2022-09-05 | Genentech Inc | Formulaciones de anticuerpos anti-pd-l1 |
CU20190104A7 (es) | 2019-12-17 | 2021-08-06 | Ct Inmunologia Molecular | Formulación estable del anticuerpo nimotuzumab |
MX2022007613A (es) | 2019-12-18 | 2022-07-19 | Teneofour Inc | Union de anticuerpos de cadena pesada a cd38. |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
JP2023516377A (ja) * | 2020-03-04 | 2023-04-19 | 上海復宏漢霖生物技術股▲フン▼有限公司 | ベバシズマブを含む薬物製剤 |
GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
EP4186564A1 (en) | 2020-04-29 | 2023-05-31 | Teneoone, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
UY39191A (es) | 2020-04-29 | 2021-11-30 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |
GB202007655D0 (en) | 2020-05-22 | 2020-07-08 | King S College London | Chimeric nkg2d protein |
CN113827717A (zh) * | 2020-06-23 | 2021-12-24 | 三生国健药业(上海)股份有限公司 | 抗her2单克隆抗体冻干制剂及制备方法 |
US20230257473A1 (en) | 2020-06-30 | 2023-08-17 | Teneobio, Inc. | Multi-specific antibodies binding to bcma |
TW202216211A (zh) | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | 抗asgr1抗體共軛物及其用途 |
EP4229094A1 (en) | 2020-10-16 | 2023-08-23 | QLSF Biotherapeutics, Inc. | Multispecific binding compounds that bind to pd-l1 |
TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
JP2024501721A (ja) * | 2020-12-30 | 2024-01-15 | 上海宝済薬業股▲ふん▼有限公司 | 組換えヒトヒアルロニダーゼ製剤およびその用途 |
EP4298128A1 (en) * | 2021-02-23 | 2024-01-03 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Methods of preventing, alleviating or treating tumors |
EP4298130A2 (en) | 2021-02-25 | 2024-01-03 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
EP4298129A1 (en) | 2021-02-26 | 2024-01-03 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
BR112023019385A2 (pt) | 2021-03-23 | 2023-12-05 | King S College London | Composições compreendendo polipeptídeos de fusão nkg2d, cxcr2 e dap10/dap12 e seus métodos de uso |
TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
JP2024514107A (ja) | 2021-04-06 | 2024-03-28 | テネオバイオ, インコーポレイテッド | 抗cd19抗体及びcar-t構造体 |
IL306045A (en) | 2021-04-16 | 2023-11-01 | Teneobio Inc | Anti-CD20 antibodies and chimeric T-antigen receptor constructs |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
WO2023019556A1 (zh) * | 2021-08-20 | 2023-02-23 | 齐鲁制药有限公司 | 一种高浓度抗her2的抗体制剂及其用途 |
WO2023064876A1 (en) | 2021-10-14 | 2023-04-20 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
GB202214120D0 (en) | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US533A (en) | 1837-12-26 | Truss for hermta | ||
US4943A (en) | 1847-01-26 | Harness-buckle | ||
US2795529A (en) | 1954-06-17 | 1957-06-11 | American Home Prod | Stabilized hyaluronidase solution containing calcium chloride |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
AU639726B2 (en) | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
JPH08504172A (ja) | 1992-06-30 | 1996-05-07 | オンコロジクス,インコーポレイティド | 抗−erbB−2モノクロナール抗体の組み合わせ物及び使用方法 |
DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
RU2154649C2 (ru) | 1994-07-21 | 2000-08-20 | Акцо Нобель Н.В. | Композиции на основе циклических перекисей кетона |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5573186A (en) | 1995-03-20 | 1996-11-12 | Moen Incorporated | Stationary venturi diverter valve |
ES2332984T3 (es) | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
WO1996040210A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP0845997A1 (en) | 1995-07-27 | 1998-06-10 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
ES2198913T5 (es) | 1998-05-06 | 2013-11-18 | Genentech, Inc. | Purificación de proteínas mediante cromatografía de intercambio iónico |
KR100797308B1 (ko) | 1999-06-25 | 2008-01-23 | 제넨테크, 인크. | 인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법 |
US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
ES2332402T5 (es) | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
DE10153197A1 (de) | 2001-10-27 | 2003-05-08 | Merck Patent Gmbh | Pigment mit Metallglanz |
EP1475101B1 (en) | 2002-02-14 | 2010-10-27 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing solution pharmaceuticals |
TW555245U (en) | 2003-01-29 | 2003-09-21 | Hon Hai Prec Ind Co Ltd | Cable connector assembly |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
EP2311973A1 (en) | 2003-03-05 | 2011-04-20 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
PL2335725T3 (pl) | 2003-04-04 | 2017-04-28 | Genentech, Inc. | Preparaty zawierające wysokoskoncentrowane przeciwciała i białka |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
MX369959B (es) | 2003-05-14 | 2019-11-27 | Immunogen Inc | Composicion de farmaco conjugado. |
MXPA06002159A (es) | 2003-08-26 | 2006-05-22 | Becton Dickinson Co | Metodos para la administracion intradermica de agentes terapeuticos. |
KR20120064120A (ko) * | 2004-06-01 | 2012-06-18 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
ZA200701234B (en) | 2004-07-22 | 2008-12-31 | Genentech Inc | HER2 antibody composition |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
MX2007009091A (es) | 2005-01-28 | 2008-01-11 | Wyeth Corp | Formulaciones de polipeptido liquidas estabilizadas. |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
KR20080104160A (ko) | 2006-03-28 | 2008-12-01 | 에프. 호프만-라 로슈 아게 | 항-igf-1r 인간 단일클론 항체 제형 |
US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
JP5070993B2 (ja) | 2007-08-27 | 2012-11-14 | 富士通株式会社 | 音処理装置、位相差補正方法及びコンピュータプログラム |
CN101918579A (zh) * | 2007-10-22 | 2010-12-15 | 先灵公司 | 完全人抗-vegf抗体和使用方法 |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
TWI532498B (zh) * | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
KR101251152B1 (ko) | 2008-09-10 | 2013-04-05 | 에프. 호프만-라 로슈 아게 | 치료용 약물과 함께 사용하기 위한 전달 장치 |
US7905299B2 (en) | 2008-09-18 | 2011-03-15 | Longyear Tm, Inc. | Articulation assembly for moving a drill mast |
WO2010031720A2 (en) | 2008-09-19 | 2010-03-25 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
WO2010138918A1 (en) | 2009-05-29 | 2010-12-02 | Pacira Pharmaceuticals, Inc. | Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
US20130236448A1 (en) | 2009-08-04 | 2013-09-12 | F. Hoffmann-La Roche Ag (Roche Glycart Ag) | Concentrated polypeptide formulations with reduced viscosity |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
KR20220070586A (ko) | 2010-11-08 | 2022-05-31 | 제넨테크, 인크. | 피하 투여용 항―il―6 수용체 항체 |
-
2010
- 2010-07-27 US US12/804,703 patent/US9345661B2/en active Active
- 2010-07-28 EA EA201200204A patent/EA027553B1/ru active Protection Beyond IP Right Term
- 2010-07-28 EP EP13166031.8A patent/EP2687202B1/en active Active
- 2010-07-28 KR KR1020137008026A patent/KR101769652B1/ko active IP Right Grant
- 2010-07-28 PE PE2013000301A patent/PE20131324A1/es active IP Right Grant
- 2010-07-28 IN IN961CHN2012 patent/IN2012CN00961A/en unknown
- 2010-07-28 BR BR112012002080A patent/BR112012002080A2/pt not_active Application Discontinuation
- 2010-07-28 PL PL10737891.1T patent/PL2459167T5/pl unknown
- 2010-07-28 UA UAA201300938A patent/UA104254C2/ru unknown
- 2010-07-28 SI SI201032130T patent/SI2687202T1/sl unknown
- 2010-07-28 ES ES10737891T patent/ES2413090T5/es active Active
- 2010-07-28 EP EP10737891.1A patent/EP2459167B2/en active Active
- 2010-07-28 HU HUE13166031A patent/HUE062122T2/hu unknown
- 2010-07-28 CA CA2768458A patent/CA2768458C/en active Active
- 2010-07-28 KR KR1020127005268A patent/KR101413947B1/ko active IP Right Grant
- 2010-07-28 PE PE2012000105A patent/PE20120665A1/es active IP Right Grant
- 2010-07-28 CN CN202111089810.5A patent/CN113967194A/zh active Pending
- 2010-07-28 RS RS20230476A patent/RS64314B1/sr unknown
- 2010-07-28 FI FIEP13166031.8T patent/FI2687202T3/fi active
- 2010-07-28 DK DK10737891.1T patent/DK2459167T3/da active
- 2010-07-28 RS RS20130343A patent/RS52913B2/sr unknown
- 2010-07-28 PL PL13166031.8T patent/PL2687202T3/pl unknown
- 2010-07-28 MA MA34587A patent/MA33471B1/fr unknown
- 2010-07-28 AU AU2010277657A patent/AU2010277657B2/en active Active
- 2010-07-28 HR HRP20230462TT patent/HRP20230462T1/hr unknown
- 2010-07-28 HR HRP20130697TT patent/HRP20130697T4/hr unknown
- 2010-07-28 CN CN201080043414.2A patent/CN102573789B/zh active Active
- 2010-07-28 MX MX2012001124A patent/MX2012001124A/es active IP Right Grant
- 2010-07-28 SI SI201030218T patent/SI2459167T2/sl unknown
- 2010-07-28 PT PT131660318T patent/PT2687202T/pt unknown
- 2010-07-28 MX MX2013009895A patent/MX355450B/es unknown
- 2010-07-28 EA EA201400270A patent/EA031013B1/ru active Protection Beyond IP Right Term
- 2010-07-28 SG SG2013056155A patent/SG193146A1/en unknown
- 2010-07-28 EP EP23172095.4A patent/EP4257150A3/en active Pending
- 2010-07-28 ES ES13166031T patent/ES2948033T3/es active Active
- 2010-07-28 UA UAA201201888A patent/UA102166C2/ru unknown
- 2010-07-28 NZ NZ597190A patent/NZ597190A/xx unknown
- 2010-07-28 CN CN201510673057.2A patent/CN105168125A/zh active Pending
- 2010-07-28 PT PT107378911T patent/PT2459167E/pt unknown
- 2010-07-28 MY MYPI2012000396A patent/MY163001A/en unknown
- 2010-07-28 WO PCT/EP2010/060930 patent/WO2011012637A2/en active Application Filing
- 2010-07-28 DK DK13166031.8T patent/DK2687202T3/da active
- 2010-07-28 NZ NZ603900A patent/NZ603900A/en unknown
- 2010-07-28 MY MYPI2014002480A patent/MY172245A/en unknown
- 2010-07-28 SG SG2012006748A patent/SG178185A1/en unknown
- 2010-07-28 LT LTEP13166031.8T patent/LT2687202T/lt unknown
- 2010-07-28 JP JP2012522158A patent/JP5462944B2/ja active Active
- 2010-07-28 EP EP23206430.3A patent/EP4339212A2/en active Pending
- 2010-07-29 AR ARP100102752A patent/AR077605A1/es not_active Application Discontinuation
- 2010-07-30 TW TW102110768A patent/TWI474834B/zh active
- 2010-07-30 TW TW099125487A patent/TWI401089B/zh active
-
2011
- 2011-12-16 CR CR20110679A patent/CR20110679A/es unknown
- 2011-12-21 ZA ZA2011/09459A patent/ZA201109459B/en unknown
- 2011-12-26 CO CO11178794A patent/CO6430421A2/es not_active Application Discontinuation
-
2012
- 2012-01-05 IL IL217382A patent/IL217382A/en active IP Right Grant
- 2012-01-16 TN TNP2012000023A patent/TN2012000023A1/en unknown
- 2012-01-30 GT GT201200024A patent/GT201200024A/es unknown
- 2012-01-31 CL CL2012000269A patent/CL2012000269A1/es unknown
- 2012-01-31 EC EC2012011643A patent/ECSP12011643A/es unknown
- 2012-10-17 ZA ZA2012/07815A patent/ZA201207815B/en unknown
- 2012-11-02 HK HK16103046.0A patent/HK1215157A1/zh unknown
- 2012-11-02 HK HK12111047.6A patent/HK1172236A1/xx unknown
-
2013
- 2013-03-15 US US13/833,316 patent/US20130216532A1/en not_active Abandoned
- 2013-06-11 JP JP2013123231A patent/JP5878144B2/ja active Active
- 2013-07-22 CY CY20131100613T patent/CY1114185T1/el unknown
- 2013-09-05 CL CL2013002550A patent/CL2013002550A1/es unknown
-
2015
- 2015-10-06 DO DO2015000255A patent/DOP2015000255A/es unknown
-
2016
- 2016-02-25 US US15/053,217 patent/US9968676B2/en active Active
-
2017
- 2017-06-30 AR ARP170101828A patent/AR108936A2/es not_active Application Discontinuation
- 2017-08-10 IL IL253941A patent/IL253941B/en unknown
-
2018
- 2018-04-10 US US15/949,616 patent/US20180228895A1/en not_active Abandoned
-
2021
- 2021-07-27 US US17/443,780 patent/US20210353753A1/en not_active Abandoned
-
2023
- 2023-06-02 EC ECSENADI202341058A patent/ECSP23041058A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253941B (en) | A subcutaneous preparation of an antibody against her2 | |
HRP20160754T1 (hr) | Formulacija protutijela | |
ZA201204266B (en) | Antibody formulation | |
ZA201106503B (en) | Antibody formulation | |
ZA201203242B (en) | Antibody formulation | |
EP2409990A4 (en) | VARIANT OF A CONSTANT ANTIBODY REGION | |
EP2409991A4 (en) | VARIANT OF A CONSTANT REGION OF ANTIBODIES | |
EP2358392A4 (en) | ANTIBODY FORMULATION | |
ZA201104545B (en) | Anti-siglec-15 antibody | |
ZA201101343B (en) | Novel antibody formulation | |
HRP20141257T1 (en) | Antibodies against her2 truncated variant ctf-611 | |
EP2400984A4 (en) | HER2 ANTIBODY COMPOSITIONS | |
GB2473934B (en) | Anti-VEEV antibody | |
GB0911712D0 (en) | Antibody |